Improving Atopic Dermatitis Treatment for Adolescents
1 day ago · In adolescents with moderate to severe atopic dermatitis, a Janus kinase (JAK)-selective inhibitor has been shown to maintain high levels of improvement in symptoms and long-term quality of life after 76 weeks with strong evidence of safety, according to a recent Northwestern Medicine-led analysis of three international, randomized clinical trials published in JAMA Dermatology.
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
2 days ago · The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and children aged 2 years and older. Tapinarof is an aryl hydrocarbon receptor agonist currently marketed ...
Dupilumab for Atopic Dermatitis Sustained Efficacy in Clinical …
3 days ago · Treatment of atopic dermatitis with dupilumab therapy over 3 years sustains efficacy in patient-reported outcomes (PROs) and clinical signs, new findings suggest, with tolerable levels of safety among Japanese patients with the inflammatory skin condition. 1. These data were the conclusion of new research conducted in Japan within a single center, with assessments of patients occurring between ...
Atopic dermatitis - Latest research and news | Nature
Nov 6, 2024 · Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory familial disease of the skin. It is characterized by an increased ability to form immunoglobulin E and a tendency to...
Atopic dermatitis: New drug significantly improves symptoms
Sep 23, 2024 · For people with atopic dermatitis, a new drug targeting the condition has just been approved by the FDA. The drug, from Eli Lilly, inhibits the action of a cytokine believed to be the primary...
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Mar 15, 2023 · Eligible patients with moderate-to-severe atopic dermatitis (adults [≥18 years of age] and adolescents [12 to <18 years of age, weighing ≥40 kg]) were randomly assigned in a 2:1 ratio to ...
New Treatment for Moderate to Severe Atopic Dermatitis ...
(December 09, 2022) Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.
Atopic dermatitis: an expanding therapeutic pipeline for a ...
Aug 20, 2021 · Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing...
American Academy of Dermatology issues updated ...
ROSEMONT, Ill. (January 11, 2023) — Often called eczema or atopic eczema, atopic dermatitis is a common skin condition, affecting 1 in 10 Americans. Although atopic dermatitis occurs most frequently in children, it also affects adults and can have a …
Atopic Dermatitis | New England Journal of Medicine
Mar 24, 2021 · Atopic dermatitis is one of the most prevalent inflammatory skin diseases. It usually develops in childhood and may persist into adulthood; less frequently, it starts in midlife or late life....